FDA Considers Label Changes for Keytruda, Opdivo and Yervoy
By Zachary Brennan -
Published 12 July 2017
The US Food and Drug Administration (FDA) told Focus on Wednesday that the agency is considering labeling changes to include additional ocular inflammatory conditions for three immune checkpoint inhibitors.
Categories: News, US, FDA, Drugs, Postmarket surveillance
Tags: Opdivo, Keytruda, Yervoy, B-MS, Merck, uveitis